The prothrombotic paradox of hypertension - Role of the renin-angiotensin and kallikrein-kinin systems

被引:74
作者
Dielis, AWJH
Smid, M
Spronk, HMH
Hamulyak, K
Kroon, AA
ten Cate, H
de Leeuw, PW
机构
[1] Univ Hosp Maastricht, Dept Med, NL-6202 AZ Maastricht, Netherlands
[2] Univ Maastricht, Cardiovasc Res Inst, NL-6202 AZ Maastricht, Netherlands
关键词
renin-angiotensin system; kallikrein-kinin systems; blood pressure;
D O I
10.1161/01.HYP.0000193538.20705.23
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Despite increased pulsatile stress, thrombotic rather than hemorrhagic events represent a major complication of hypertension. The pathophysiology of thrombosis in hypertension involves the interaction among vascular endothelium and particularly the renin-angiotensin and kallikrein-kinin systems. Because hypertension is often associated with some degree of inflammation, the combination of chronic inflammation and chronic shear stress may convert the normal anticoagulant endothelium into a procoagulant surface, expressing tissue factor. Activation of the renin- angiotensin system leads to activation of nuclear factor kappa B-dependent proinflammatory genes, also accelerating the expression of tissue factor. Renin-angiotensin and kallikrein-kinin systems interact at several levels to modulate coagulation, fibrinolysis, and vasodilatation in such a way that these 2 systems could have a major influence on the occurrence of thrombotic complications. Treatment with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists may favorably influence the balance between the renin-angiotensin and kallikrein-kinin axis, regulating blood pressure as well as reducing the risk of thrombosis, which may explain part of the clinical efficacy of these drugs.
引用
收藏
页码:1236 / 1242
页数:7
相关论文
共 63 条
[31]   Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol [J].
Makris, TK ;
Stavroulakis, GA ;
Krespi, PG ;
Hatzizacharias, AN ;
Triposkiadis, FK ;
Tsoukala, CG ;
Votteas, VV ;
Kyriakidis, MK .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (07) :783-788
[32]   Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells [J].
Mehta, JL ;
Li, DY ;
Yang, H ;
Raizada, MK .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2002, 39 (06) :789-794
[33]   Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator [J].
Moreira, CR ;
Schmaier, AH ;
Mahdi, F ;
da Motta, G ;
Nader, HB ;
Shariat-Madar, Z .
FEBS LETTERS, 2002, 523 (1-3) :167-170
[34]   Angiotensin II (AT1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy [J].
Müller, DN ;
Mervaala, EMA ;
Dechend, R ;
Fiebeler, A ;
Park, JK ;
Schmidt, F ;
Theuer, J ;
Breu, V ;
Mackman, N ;
Luther, T ;
Schneider, W ;
Gulba, D ;
Ganten, D ;
Haller, H ;
Luft, FC .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (01) :111-122
[35]   Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes [J].
Napoleone, E ;
Di Santo, A ;
Camera, M ;
Tremoli, E ;
Lorenzet, R .
CIRCULATION RESEARCH, 2000, 86 (02) :139-143
[36]  
Nemerson Y, 1998, BLOOD COAGUL FIBRIN, V9, pS45
[37]   Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4 [J].
Nieman, MT ;
Pagan-Ramo, E ;
Warnock, M ;
Krijanovski, Y ;
Hasan, AAK ;
Schmaier, AH .
FEBS LETTERS, 2005, 579 (01) :25-29
[38]  
Nishimura H, 1999, THROMB HAEMOSTASIS, V82, P1516
[39]  
Nishimura H, 1997, THROMB HAEMOSTASIS, V77, P1189
[40]   Increased renal vascular sensitivity to angiotensin II in hypertension is due to decreased response to prostaglandins [J].
Palmgren, E ;
Widgren, B ;
Aurell, M ;
Herlitz, H .
JOURNAL OF HYPERTENSION, 2003, 21 (05) :969-976